Besifloxacin: A topical fluoroquinolone for the treatment of bacterial conjunctivitis

Clinical Therapeutics

Volumn 32, Issue 3, 2010, Pages 454-471

  Chang, Mei H ^a   Fung, Horatio B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bacterial conjunctivitis; Besifloxacin; Ophthalmic fluoroquinolones

Indexed keywords

BESIFLOXACIN; CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CORNEA DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; DERMATITIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EYE DISCHARGE; EYE IRRITATION; EYE PAIN; EYELID EDEMA; HAEMOPHILUS INFLUENZAE; HUMAN; HYPEREMIA; IC 50; IRITIS; LACRIMATION; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OCULAR PRURITUS; PATIENT COMPLIANCE; PHOTOPHOBIA; PUNCTATE KERATITIS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS PNEUMONIAE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VIRAL CONJUNCTIVITIS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZEPINES; CLINICAL TRIALS AS TOPIC; CONJUNCTIVITIS, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; OPHTHALMIC SOLUTIONS; TREATMENT OUTCOME;

EID: 77951908241     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.013     Document Type: Article

References (33)

1. Tarabishy AB, Jeng BH Bacterial conjunctivitis: A review for internists. Cleve Clin J Med. 2008, 75:507-512.
2. Chung CW, Cohen EJ Eye disorders: Bacterial conjunctivitis. West J Med. 2000, 173:202-205.
3. McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009, 116:1615-1623.
4. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009, 25:1159-1169.
5. Silverman MA, Bessman E Conjunctivitis. Emedicine June 1, 2009, Accessed December 28, 2009. http://emedicine.medscape.com/article/797874-overview.
6. Smith AF, Waycaster C Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States. BMC Ophthalmol. 2009, 9:13.
7. Fransen L, Van den Berghe P, Mertens A, et al. Incidence and bacterial aetiology of neonatal conjunctivitis. Eur J Pediatr. 1987, 146:152-155.
8. Teoh DL, Reynolds S Diagnosis and management of pediatric conjunctivitis. Pediatr Emerg Care. 2003, 19:48-55.
9. Mueller JB, McStay CM Ocular infection and inflammation. Emerg Med Clin North Am. 2008, 26:57-72.
10. Topical antibiotics. In: Melton R, Thomas R. 2009 Clinical Guide to Ophthalmic Drugs: A Supplement to Review of Optometry. 2009:4A-9A.
11. Lohr JA, Austin RD, Grossman M, et al. Comparison of three topical antimicrobials for acute bacterial conjunctivitis. Pediatr Infect Dis J. 1988, 7:626-629.
12. Weiss A Acute conjunctivitis in childhood. Curr Probl Pediatr. 1994, 24:4-11.
13. Wallace DK, Steinkuller PG Ocular medications in children. Clin Pediatr (Phila). 1998, 37:645-652.
14. Adverse systemic effects from ophthalmic drugs. Med Lett Drugs Ther. 1982, 24:53-54.
15. 2009 Drug Topics Red Book 2009, Thomson Medical Economics, Montvale, NJ.
16. September 2009 Drug Topics Red Book Update 2009, Thomson Medical Economics, Montvale, NJ.
17. NDA 22-308. NDA approval US Dept of Health and Human Services, Accessed August 10, 2009. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022308s000ltr.pdf.
18. Besivance [package insert] 2009, Bausch & Lomb Incorporated, Tampa, Fla.
19. Besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis Dermatologic and Ophthalmic Drugs Advisory Committee Meeting Briefing Document, Accessed August 10, 2009. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4397b1-02-BauschLomb.pdf.
20. Arnold DR, Granvil CP, Ward KW, Proksch JW Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008, 867:105-110.
21. Ward KW, Lepage JF, Driot JY Non-clinical pharmacodynamics, pharmacokinetics, and safety of BOL303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther. 2007, 23:243-256.
22. Smith A, Pennefather PM, Kaye SB, Hart CA Fluoroquinolones: Place in ocular therapy. Drugs 2001, 61:747-761.
23. Katzung BG Sulfonamides, trimethoprim, and quinolones. Basic & Clinical Pharmacology 2004, 777-781. Lange Medical Books/ McGraw-Hill, New York, NY. 9th ed.
24. Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009, 63:443-450.
25. Zhang JZ, Cavet ME, Ward KW Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells. Curr Eye Res. 2008, 33:923-932.
26. Zhang JZ, Ward KW Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008, 61:111-116.
27. Goldstein MH, Kowalski RP, Gordon YJ Emerging fluoroquinolone resistance in bacterial keratitis: A 5-year review. Ophthalmology 1999, 106:1313-1318.
28. Shigemura K, Arakawa S, Miura T, et al. Significance of fluoroquinoloneresistant Escherichia coli in urinary tract infections. Jpn J Infect Dis. 2008, 61:226-228.
29. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA. 2003, 289:885-888.
30. Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroqui- nolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009, 53:3552-3560.
31. Proksch JW, Granvil CP, Siou-Mermet R, et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009, 25:335-344.
32. Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, doublemasked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009, 31:514-526.
33. Leeming JP Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet. 1999, 37:351-360.